The Effect of Hormone Replacement Therapy on the Survival of UK Women: a Retrospective Cohort Study 1984-2017

Overview

Journal BJOG

Specialty Gynecology & Obstetrics

Date 2021 Nov 13

PMID 34773357

Citations 4

Authors

N Akter

E Kulinskaya

N Steel

I Bakbergenuly

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate the effect of estrogen-only and combined hormone replacement therapy (HRT) on the hazards of overall and age-specific all-cause mortality in healthy women aged 46-65 at first prescription.

Design: Matched cohort study.

Setting: Electronic primary care records from The Health Improvement Network (THIN) database, UK (1984-2017).

Population: 105 199 HRT users (cases) and 224 643 non-users (controls) matched on age and general practice.

Methods: Weibull-Double-Cox regression models adjusted for age at first treatment, birth cohort, type 2 diabetes, hypertension and hypertension treatment, coronary heart disease, oophorectomy, hysterectomy, body mass index, smoking and deprivation status.

Main Outcome Measures: All-cause mortality.

Results: A total of 21 751 women died over an average of 13.5 years follow-up per participant, of whom 6329 were users and 15 422 non-users. The adjusted hazard ratio (HR) of overall all-cause mortality in combined HRT users was 0.91 (95% CI 0.88-0.94), and in estrogen-only users was 0.99 (0.93-1.07), compared with non-users. Age-specific adjusted HRs for participants aged 46-50, 51-55, 56-60 and 61-65 years at first treatment were 0.98 (0.92-1.04), 0.87 (0.82-0.92), 0.88 (0.82-0.93) and 0.92 (0.85-0.98) for combined HRT users compared with non-users, and 1.01 (0.84-1.21), 1.03 (0.89-1.18), 0.98 (0.86-1.12) and 0.93 (0.81-1.07) for estrogen-only users, respectively.

Conclusions: Combined HRT was associated with a 9% lower risk of all-cause mortality and estrogen-only formulation was not associated with any significant changes.

Tweetable Abstract: Estrogen-only HRT is not associated with all-cause mortality and combined HRT reduces the risks.

Citing Articles

QbD-Driven preparation, characterization, and pharmacokinetic investigation of daidzein-l oaded nano-cargos of hydroxyapatite.

Gautam N, Dutta D, Mittal S, Alam P, Emad N, Al-Sabri M Sci Rep. 2025; 15(1):2967.

PMID: 39848966 PMC: 11757988. DOI: 10.1038/s41598-025-85463-8.

Effects of Hormonal Replacement Therapy and Mindfulness-Based Stress Reduction on Climacteric Symptoms Following Risk-Reducing Salpingo-Oophorectomy.

Ali A, Al-Dossary S, Laranjeira C, Amer F, Hallit S, Alkhamees A Healthcare (Basel). 2024; 12(16).

PMID: 39201170 PMC: 11353799. DOI: 10.3390/healthcare12161612.

Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis.

Phua T Front Aging. 2023; 4:1196648.

PMID: 37384143 PMC: 10293850. DOI: 10.3389/fragi.2023.1196648.

A double-Cox model for non-proportional hazards survival analysis with frailty.

Begun A, Kulinskaya E, Ncube N Stat Med. 2023; 42(18):3114-3127.

PMID: 37190904 PMC: 10946853. DOI: 10.1002/sim.9760.

The effect of hormone replacement therapy on the survival of UK women: a retrospective cohort study 1984-2017.

Akter N, Kulinskaya E, Steel N, Bakbergenuly I BJOG. 2021; 129(6):994-1003.

PMID: 34773357 PMC: 9298998. DOI: 10.1111/1471-0528.17008.

References

Springate D, Kontopantelis E, Ashcroft D, Olier I, Parisi R, Chamapiwa E . ClinicalCodes: an online clinical codes repository to improve the validity and reproducibility of research using electronic medical records. PLoS One. 2014; 9(6):e99825. PMC: 4062485. DOI: 10.1371/journal.pone.0099825. View

Bromley S, de Vries C, Farmer R . Utilisation of hormone replacement therapy in the United Kingdom. A descriptive study using the general practice research database. BJOG. 2004; 111(4):369-76. DOI: 10.1111/j.1471-0528.2004.00082.x. View

Malek A, Vladutiu C, Meyer M, Cushman M, Newman R, Lisabeth L . The association of age at menopause and all-cause and cause-specific mortality by race, postmenopausal hormone use, and smoking status. Prev Med Rep. 2019; 15:100955. PMC: 6651856. DOI: 10.1016/j.pmedr.2019.100955. View

Schuetz F, Diel I, Pueschel M, von Holst T, Solomayer E, Lange S . Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol. 2007; 196(4):342.e1-9. DOI: 10.1016/j.ajog.2006.10.901. View

Grodstein F, Stampfer M, Colditz G, Willett W, Manson J, Joffe M . Postmenopausal hormone therapy and mortality. N Engl J Med. 1997; 336(25):1769-75. DOI: 10.1056/NEJM199706193362501. View

Salpeter S, Cheng J, Thabane L, Buckley N, Salpeter E . Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009; 122(11):1016-1022.e1. DOI: 10.1016/j.amjmed.2009.05.021. View

Grodstein F, Manson J, Colditz G, Willett W, Speizer F, Stampfer M . A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000; 133(12):933-41. DOI: 10.7326/0003-4819-133-12-200012190-00008. View

Beral V, Bull D, Reeves G . Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005; 365(9470):1543-51. DOI: 10.1016/S0140-6736(05)66455-0. View

Begun A, Kulinskaya E, MacGregor A . Risk-adjusted cUSUM control charts for shared frailty survival models with application to hip replacement outcomes: a study using the NJR dataset. BMC Med Res Methodol. 2019; 19(1):217. PMC: 6882343. DOI: 10.1186/s12874-019-0853-2. View

10.

Marshall A, Altman D, Holder R . Comparison of imputation methods for handling missing covariate data when fitting a Cox proportional hazards model: a resampling study. BMC Med Res Methodol. 2011; 10:112. PMC: 3019210. DOI: 10.1186/1471-2288-10-112. View

11.

. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394(10204):1159-1168. PMC: 6891893. DOI: 10.1016/S0140-6736(19)31709-X. View

12.

Beral V, Bull D, Green J, Reeves G . Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007; 369(9574):1703-10. DOI: 10.1016/S0140-6736(07)60534-0. View

13.

Gillam S, Siriwardena A, Steel N . Pay-for-performance in the United Kingdom: impact of the quality and outcomes framework: a systematic review. Ann Fam Med. 2012; 10(5):461-8. PMC: 3438214. DOI: 10.1370/afm.1377. View

14.

Persson I, Yuen J, Bergkvist L, Schairer C . Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer. 1996; 67(3):327-32. DOI: 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T. View

15.

Blak B, Thompson M, Dattani H, Bourke A . Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2012; 19(4):251-5. DOI: 10.14236/jhi.v19i4.820. View

16.

Ettinger B, Friedman G, Bush T, Quesenberry Jr C . Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996; 87(1):6-12. DOI: 10.1016/0029-7844(95)00358-4. View

17.

Stram D, Liu Y, Henderson K, Sullivan-Halley J, Luo J, Saxena T . Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause. 2010; 18(3):253-61. PMC: 3253313. DOI: 10.1097/gme.0b013e3181f0839a. View

18.

Benkhadra K, Mohammed K, Al Nofal A, Leon B, Alahdab F, Faubion S . Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015; 100(11):4021-8. DOI: 10.1210/jc.2015-2238. View

19.

Akter N, Kulinskaya E, Steel N, Bakbergenuly I . The effect of hormone replacement therapy on the survival of UK women: a retrospective cohort study 1984-2017. BJOG. 2021; 129(6):994-1003. PMC: 9298998. DOI: 10.1111/1471-0528.17008. View

20.

Salpeter S, Walsh J, Greyber E, Ormiston T, Salpeter E . Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004; 19(7):791-804. PMC: 1492478. DOI: 10.1111/j.1525-1497.2004.30281.x. View